Patents by Inventor Yangli QI

Yangli QI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridinyl morpholine compound, preparation method therefor, and application thereof
    Patent number: 12410136
    Abstract: Disclosed in the present invention are a pyridinyl morpholine compound, a preparation method therefor, and an application thereof. The present invention provides a pyridinyl morpholine compound as represented by formula I, a pharmaceutically acceptable salt thereof or a hydrate of the pharmaceutically acceptable salt thereof. The compound can be used as an antagonist for one or more of D2, D3 or 5-HT2A, and is used for preparing a drug for treating schizophrenia.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: September 9, 2025
    Assignees: SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD., SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
    Inventors: Jianqi Li, Yangli Qi, Xiaowen Chen, Junwei Xu, Ruixiang Yuan, Qiang Pu
  • COMPOUNDS AS BCL-2 INHIBITORS
    Publication number: 20250122191
    Abstract: Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: November 10, 2022
    Publication date: April 17, 2025
    Inventors: Hongbin LIU, Hua XU, Weipeng ZHANG, Rui TAN, Jinhua YU, Yunling WANG, Yangli QI, Yue RONG, Zhuo HUANG, Ling CHEN, Chenglin ZHOU, Lihua JIANG, Shu LIN, Xingdong ZHAO, Weibo WANG
  • PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    Publication number: 20230242486
    Abstract: Disclosed in the present invention are a pyridinyl morpholine compound, a preparation method therefor, and an application thereof. The present invention provides a pyridinyl morpholine compound as represented by formula I, a pharmaceutically acceptable salt thereof or a hydrate of the pharmaceutically acceptable salt thereof. The compound can be used as an antagonist for one or more of D2, D3 or 5-HT2A, and is used for preparing a drug for treating schizophrenia.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Inventors: Jianqi LI, Yangli QI, Xiaowen CHEN, Junwei XU, Ruixiang YUAN, Qiang PU